176 related articles for article (PubMed ID: 3140452)
1. Therapeutic use of the OKT3 anti-T cell monoclonal antibody: mode of action and side effects.
Chatenoud L
Transplant Proc; 1988 Oct; 20(5 Suppl 6):79-83. PubMed ID: 3140452
[No Abstract] [Full Text] [Related]
2. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
Goldstein G
Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
[No Abstract] [Full Text] [Related]
3. [In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].
Chatenoud L; Bach JF
Nephrologie; 1987; 8(3):95-8. PubMed ID: 3309702
[TBL] [Abstract][Full Text] [Related]
4. OKT3 treatment of steroid- and/or anti-thymocyte globulin-resistant renal allograft rejection occurring on triple baseline immunosuppression including cyclosporine A.
Widmer U; Frei D; Keusch G; Burger HR; Largiader F; Binswanger U
Transplant Proc; 1988 Oct; 20(5 Suppl 6):90-5. PubMed ID: 3140454
[No Abstract] [Full Text] [Related]
5. Clinical development of Orthoclone OKT3.
Cosimi AB
Transplant Proc; 1987 Apr; 19(2 Suppl 1):7-16. PubMed ID: 3105142
[No Abstract] [Full Text] [Related]
6. Acute renal allograft rejection: the role of monoclonal antibodies in treatment: experience with orthoclonal anti-T3 cell antibody.
McLigeyo SO; Notghi A; Anderton JL; Dick J
East Afr Med J; 1990 Sep; 67(9):667-73. PubMed ID: 2123786
[TBL] [Abstract][Full Text] [Related]
7. Use of Orthoclone OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immunosuppressive regimens.
Monaco A; Goldstein G; Barnes L
Transplant Proc; 1987 Apr; 19(2 Suppl 1):28-31. PubMed ID: 3105137
[No Abstract] [Full Text] [Related]
8. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
Waid TH; Lucas BA; Thompson JS; Munch LC; Brown S; Kryscio R; Prebeck R; VanHoy MA; Jezek D
Transplant Proc; 1991 Feb; 23(1 Pt 2):1062-5. PubMed ID: 1899152
[No Abstract] [Full Text] [Related]
9. Immunologic monitoring in OKT3-treated kidney graft recipients.
Zlabinger GJ; Maurer D; Ulrich W; Meron G; Pohanka E; Kovarik J
Transplant Proc; 1990 Aug; 22(4):1777-8. PubMed ID: 2117807
[No Abstract] [Full Text] [Related]
10. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection.
Georgitis JW; Browning MC; Steiner D; Lorentz WB
Ann Allergy; 1991 Apr; 66(4):343-7. PubMed ID: 1901692
[TBL] [Abstract][Full Text] [Related]
11. First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti-OKT3 IgM and/or IgG immunization.
Birkeland SA; Bach JF; Chatenoud L; Jørgensen KA; Strate M; Elbirk A; Rohr N; Svendsen V
Transplant Proc; 1990 Feb; 22(1):221-2. PubMed ID: 2106740
[No Abstract] [Full Text] [Related]
12. Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodies.
Colvin RB; Preffer FI
Clin Lab Med; 1991 Sep; 11(3):693-714. PubMed ID: 1934971
[TBL] [Abstract][Full Text] [Related]
13. A U.S. clinical study of Orthoclone OKT3 in renal transplantation.
Norman DJ; Shield CF; Barry J; Henell K; Funnell MB; Lemon J
Transplant Proc; 1987 Apr; 19(2 Suppl 1):21-7. PubMed ID: 3105136
[No Abstract] [Full Text] [Related]
14. Reversing cardiac transplant rejection with Orthoclone OKT3.
Dault LA; Nagy CS; Collins JA
Am J Nurs; 1989 Jul; 89(7):953-5. PubMed ID: 2500020
[No Abstract] [Full Text] [Related]
15. The clinical role of OKT3.
Norman DJ
Cardiol Clin; 1990 Feb; 8(1):97-105. PubMed ID: 2407364
[TBL] [Abstract][Full Text] [Related]
16. [Orthoclone OKT3 (Muromonab CD3)--the indications for and manner of its use. Side effects and their prevention].
Filev A; Kumanov Kh; Slavov Ch; Tsvetkov M
Khirurgiia (Sofiia); 1989; 42(6):80-2. PubMed ID: 2517512
[TBL] [Abstract][Full Text] [Related]
17. Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use.
Emmons C; Hunsicker LG
Iowa Med; 1987 Feb; 77(2):78-82. PubMed ID: 3557906
[No Abstract] [Full Text] [Related]
18. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection.
Norman DJ; Shield CF; Henell KR; Kimball J; Barry JM; Bennett WM; Leone M
Transplantation; 1988 Oct; 46(4):523-9. PubMed ID: 3140448
[TBL] [Abstract][Full Text] [Related]
19. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
[No Abstract] [Full Text] [Related]
20. Review and preview of anti-T-cell antibodies.
Helderman JH
Transplant Proc; 1995 Oct; 27(5 Suppl 1):8-9. PubMed ID: 7482824
[No Abstract] [Full Text] [Related]
[Next] [New Search]
